Why MediciNova, Inc.’s (MNOV) Stock Is Up 10.07%
As of Monday, August 24, MediciNova, Inc.’s MNOV share price has surged by 10.07%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Commentary & Analysis
Why MediciNova, Inc.’s (MNOV) Stock Is Up 9.35%
As of Monday, August 24, MediciNova, Inc.’s MNOV share price has surged by 9.35%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why MediciNova, Inc.’s (MNOV) Stock Is Up 9.47%
As of Wednesday, July 01, MediciNova, Inc.’s MNOV share price has surged by 9.47%, which has investors questioning if this is right time to sell.Jenna Brashear
Why MediciNova, Inc.’s (MNOV) Stock Is Up 15.15%
As of Wednesday, July 01, MediciNova, Inc.’s MNOV share price has surged by 15.15%, which has investors questioning if this is right time to sell.Omar Beirat
Why MediciNova, Inc.’s (MNOV) Stock Is Up 5.60%
As of Tuesday, June 16, MediciNova, Inc.’s MNOV share price has surged by 5.60%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | MNOV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $68.4 | $292.6 | 18% |
|
| Shares Out (Mil) | 49.2 | 54.4 | 47% |
|
| Institutional Ownership | 78.0% | 93.2% | 47% |
|
| Float (Mil) | 42.3 | 40.2 | 44% |
|
| Beta | 0.62 | 0.94 | 36% |
|
| Avg Daily Volume (000s) | 34 | 544 | 24% |
|
| Price Change (52-week) |
6.1% | 59.7% | 49% |
|
| Growth | MNOV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 2.9% | (10.1%) | 44% |
|
| EPS (5yr) | 4.7% | 16.0% | 38 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (18.9%) | (15.6%) | 36% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 1 | 1 | |
| Current EPS | ($0.060) | ($0.280) | ($0.450) | |
| Month Ago EPS | ($0.060) | ($0.260) | ($0.429) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.060) | ($0.260) | ($0.429) | |
| Year/Year Chg | 27.7% | 14.3% | (214.3%) | |
| Financials | MNOV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 2% |
|
| Net Income (TTM) (Mil) | ($11) | ($43) | 29% |
|
| EPS (TTM) | ($0.219) | ($1.400) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($31) | 20% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $43 | $164 | 15% |
|
| Valuation | MNOV | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.83 | 2.83 | 46% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MNOV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 37.7% | 64.2% | 46% |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (23.8%) | (47.5%) | 19% |
|
| ROE | (25.6%) | (55.0%) | 21% |
|
| Liabilities to Assets | 7.8% | 29.6% | 4% |
|
| F-Score | 2 | 3 | 7% |
|
MediciNova, Inc. did not pass any screens on 8/21/2026.
